FDA Expands OTC CGM Access to Children
The device was previously cleared for adults aged 18 years and older in March 2024.
-
By
-
Kathryn Wighton
-
June 15, 2026
-
Objective:
To provide access to the Dexcom Stelo Glucose Biosensor System for children aged 2 years and older who do not use insulin.
Approach:
Key Findings:
- The device is designed for children aged 2 years and older.
- Each sensor lasts up to 15 days, with potential shorter wear time in pediatric patients.
- Mild adverse events reported include local infection, skin irritation, and discomfort.
Interpretation:
The device is not suitable for patients with problematic hypoglycemia or those receiving dialysis.
Limitations:
- Does not provide alerts for low glucose levels.
- Patients with a history of disordered eating should consult a healthcare provider before use.
Conclusion:
The clearance aligns with the FDA's initiative to support home healthcare devices.
Sources: